

**Terminal Disclaimer To Obviate A Double
Patenting Rejection Over A Prior Patent**

 Docket No.
ISP#-0569

In Re Application Of: Anderson et al.

 Serial No.
09/853,409

 Filing Date
May 11, 2001

 Examiner
David Guzo

 Group Art Unit
1636

Invention: COMPOSITIONS AND METHODS FOR TREATMENT OF HEPATITIS C VIRUS-ASSOCIATED DISEASES

Owner of Record: Isis Pharmaceuticals, Inc.

TO THE COMMISSIONER FOR PATENTS:

The above-identified owner of record of a 100% percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173, as presently shortened by any terminal disclaimer, of prior Patent No. 6,608,391. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors and/or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

Check either box 1 or 2 below, if appropriate.

1. ☐ For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

2. ☒ The undersigned is an attorney of record.

02/03/2004 CRESSAU 00000004 501619 09853409

Dated: January 21, 2004

01 FC:184 Jane Massey Licata

Typed or Printed Name

Terminal disclaimer fee under 37 C.F.R. 1.204(d) included.

No fee is required for terminal disclaimer if terminal disclaimer is unchanged.

A fee of \$110.00 is required if terminal disclaimer is signed by the assignee.

110.00 DA

CERTIFICATE OF TRANSMISSION BY FACSIMILE (37 CFR 1.8)			Docket No.
Applicant(s): Anderson et al.			ISPH-0569
Serial No. 09/853,409	Filing Date May 11, 2001	Examiner David Cuzo	Group Art Unit 1636
Invention: COMPOSITIONS AND METHODS FOR TREATMENT OF HEPATITIS C VIRUS-ASSOCIATED DISEASES			
<p>I hereby certify that this <u>Terminal Disclaimer</u> (Identify type of correspondence)</p> <p>is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. <u>703-572-9306</u>)</p> <p>on <u>January 21, 2004</u> (Date)</p> <p><u>Jane Massey Licata</u> (Typed or Printed Name of Person Signing Certificate)</p> <p><u>Jane Massey Licata</u> (Signature)</p>			
Note: Each paper must have its own certificate of mailing.			

PISPH-0569